These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

87 related items for PubMed ID: 9268187

  • 1. Absolute and comparative subcutaneous bioavailability of ardeparin sodium, a low molecular weight heparin.
    Troy S, Fruncillo R, Ozawa T, Mammen E, Holloway S, Chiang S.
    Thromb Haemost; 1997 Aug; 78(2):871-5. PubMed ID: 9268187
    [Abstract] [Full Text] [Related]

  • 2. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
    Feng L, Shen-Tu J, Liu J, Chen J, Wu L, Huang M.
    Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Monitoring the anticoagulant effects of a low molecular weight heparin preparation. Correlation of assays in orthopedic surgery patients receiving ardeparin sodium for prophylaxis of deep venous thrombosis.
    Kessler CM, Esparraguera IM, Jacobs HM, Druy E, Fortune WP, Holloway DS, Giordano J, Davidson BL.
    Am J Clin Pathol; 1995 May; 103(5):642-8. PubMed ID: 7741113
    [Abstract] [Full Text] [Related]

  • 7. Comparison of the pharmacodynamic and pharmacokinetic profiles of two low-molecular-mass heparins in rats.
    Piazolo L, Harenberg J, Malsch R, Hüttner FG, Heene DL.
    Semin Thromb Hemost; 1997 May; 23(2):109-17. PubMed ID: 9200334
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins.
    Alban S, Gastpar R.
    Thromb Haemost; 2001 May; 85(5):824-9. PubMed ID: 11372675
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pharmacodynamics of intravenous and subcutaneous tinzaparin and heparin in healthy volunteers.
    Fossler MJ, Barrett JS, Hainer JW, Riddle JG, Ostergaard P, van der Elst E, Sprogel P.
    Am J Health Syst Pharm; 2001 Sep 01; 58(17):1614-21. PubMed ID: 11556655
    [Abstract] [Full Text] [Related]

  • 12. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).
    Mismetti P, Laporte-Simitsidis S, Navarro C, Sié P, d'Azemar P, Necciari J, Duret JP, Gaud C, Decousus H, Boneu B.
    Thromb Haemost; 1998 Jun 01; 79(6):1162-5. PubMed ID: 9657442
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Oral administration of a microencapsulated low-molecular-weight heparin to rabbits: anti-Xa and anti-IIa profiles.
    Javot L, Sapin A, Scala-Bertola J, Vigneron C, Lecompte T, Maincent P.
    Thromb Haemost; 2010 Jun 01; 103(6):1254-67. PubMed ID: 20390227
    [Abstract] [Full Text] [Related]

  • 15. Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers.
    Barrett JS, Hainer JW, Kornhauser DM, Gaskill JL, Hua TA, Sprogel P, Johansen K, van Lier JJ, Knebel W, Pieniaszek HJ.
    Thromb Res; 2001 Feb 15; 101(4):243-54. PubMed ID: 11248285
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin.
    Hoppensteadt DA, Walenga JM, Fasanella A, Jeske W, Fareed J.
    Thromb Res; 1995 Jan 15; 77(2):175-85. PubMed ID: 7740509
    [Abstract] [Full Text] [Related]

  • 18. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects.
    Allen A, Down G, Newland A, Reynard K, Rousell V, Salmon E, Scott R.
    Clin Ther; 2007 Jul 15; 29(7):1415-20. PubMed ID: 17825692
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of Clivarin a new low molecular weight heparin in healthy volunteers.
    Andrassy K, Eschenfelder V, Koderisch J, Weber E.
    Thromb Res; 1994 Jan 15; 73(2):95-108. PubMed ID: 7802862
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.